δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Guo, Shaocong ^a   Li, Yaqing ^b   Tong, Qi ^a   Gu, Feng ^b   Zhu, Tianhui ^a   Fu, Li ^b   Yang, Shuang ^a  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA EF1 PROTEIN; E2 BOX PROTEIN; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; TAMOXIFEN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; PROMOTER REGION; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

BREAST NEOPLASMS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; MCF-7 CELLS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TAMOXIFEN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84871357085     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052380     Document Type: Article

References (42)

1. Yamashita H, (2008) Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol 13: 380-383.
2. Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R, (2006) Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res 12: 1001s-1007s.
3. Osborne CK, Schiff R, (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62: 233-247.
4. Higgins MJ, Stearns V, (2011) Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 62: 281-293.
5. Barone I, Brusco L, Fuqua SA, (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16: 2702-2708.
6. Osborne CK, Shou J, Massarweh S, Schiff R, (2005) Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11: 865s-870s.
7. Funahashi J, Sekido R, Murai K, Kamachi Y, Kondoh H, (1993) Delta-crystallin enhancer binding protein delta EF1 is a zinc finger-homeodomain protein implicated in postgastrulation embryogenesis. Development 119: 433-446.
8. Bellon E, Luyten FP, Tylzanowski P, (2009) delta-EF1 is a negative regulator of Ihh in the developing growth plate. J Cell Biol 187: 685-699.
9. Yang S, Zhao L, Yang J, Chai D, Zhang M, et al. (2007) deltaEF1 represses BMP-2-induced differentiation of C2C12 myoblasts into the osteoblast lineage. J Biomed Sci 14: 663-679.
10. Nishimura G, Manabe I, Tsushima K, Fujiu K, Oishi Y, et al. (2006) DeltaEF1 mediates TGF-beta signaling in vascular smooth muscle cell differentiation. Dev Cell 11: 93-104.
11. Ponticos M, Partridge T, Black CM, Abraham DJ, Bou-Gharios G, (2004) Regulation of collagen type I in vascular smooth muscle cells by competition between Nkx2.5 and deltaEF1/ZEB1. Mol Cell Biol 24: 6151-6161.
12. Darling DS, Stearman RP, Qi Y, Qiu MS, Feller JP, (2003) Expression of Zfhep/deltaEF1 protein in palate, neural progenitors, and differentiated neurons. Gene Expr Patterns 3: 709-717.
13. Terraz C, Toman D, Delauche M, Ronco P, Rossert J, (2001) delta Ef1 binds to a far upstream sequence of the mouse pro-alpha 1(I) collagen gene and represses its expression in osteoblasts. J Biol Chem 276: 37011-37019.
14. Takagi T, Moribe H, Kondoh H, Higashi Y, (1998) DeltaEF1, a zinc finger and homeodomain transcription factor, is required for skeleton patterning in multiple lineages. Development 12: 21-31.
15. Higashi Y, Moribe H, Takagi T, Sekido R, Kawakami K, et al. (1997) Impairment of T cell development in deltaEF1 mutant mice. J Exp Med 185: 1467-1479.
16. Funahashi J, Kamachi Y, Goto K, Kondoh H, (1991) Identification of nuclear factor delta EF1 and its binding site essential for lens-specific activity of the delta 1-crystallin enhancer. Nucleic Acids Res 19: 3543-3547.
17. Lorenzatti G, Huang W, Pal A, Cabanillas AM, Kleer CG, (2011) CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer. JCell Sci 124: 1752-1758.
18. Hu F, Wang C, Guo S, Sun W, Mi D, et al. (2011) δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochim Biophys Acta 1809: 200-210.
19. Du J, Yang S, An D, Hu F, Yuan W, et al. (2009) BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res 19 487-496.
20. Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, et al. (2011) Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer 104: 1038-1048.
21. Haddad Y, Choi W, McConkey DJ, (2009) Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines. Clin Cancer Res 1: 532-542.
22. Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, et al. (2006) The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 66: 3893-3902.
23. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, et al. (2007) The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26: 6979-6988.
24. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, et al. (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593-601.
25. Yang S, Du J, Wang Z, Yuan W, Qiao Y, et al. (2007) BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells. BMC Cancer 7: 211.
26. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler ZS, et al. (2005) DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24 2375-2385.
27. Hu F, Wang C, Du J, Sun W, Yan J, et al. (2010) DeltaEF1 promotes breast cancer cell proliferation through down-regulating p21 expression. Biochim Biophys Acta 1802: 301-312.
28. Dillner NB, Sanders MM, (2002) Upstream stimulatory factor (USF) is recruited into a steroid hormone-triggered regulatory circuit by the estrogen-inducible transcription factor delta EF1. J Biol Chem 277: 33890-33894.
29. Dillner NB, Sanders MM, (2002) The zinc finger/homeodomain protein deltaEF1 mediates estrogen-specific induction of the ovalbumin gene. Mol Cell Endocrinol 192: 85-91.
30. Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, et al. (2006) Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr. Relat Cancer 13: 1121-1133.
31. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N, (2005) Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 239: 27-36.
32. Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, et al. (2011) Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13: R21.
33. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, et al. (2004) Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 5: 597-605.
34. Frasor J, Weaver A, Pradhan M, Dai Y, Miller LD, et al. (2009) Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 69: 8918-8925.
35. Ellison-Zelski SJ, Solodin NM, Alarid ET, (2009) Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Mol Cell Biol 29: 4949-4958.
36. Ring A, Dowsett M, (2004) A Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11: 643-658.
37. Barone I, Brusco L, Fuqua SA, (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16: 2702-2708.
38. Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, et al. (1998) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 58: 2515-2519.
39. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, et al. (2001) Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 61: 7025-7029.
40. Vesuna F, Lisok A, Kimble B, Domek J, Kato Y, et al. (2012) Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α. Oncogene 31: 3223-3234.
41. Yamamoto H, Mukaisho K, Sugihara H, Hattori T, Asano S, (2011) Down-regulation of FXYD3 is induced by transforming growth factor-β signaling via ZEB1/δEF1 in human mammary epithelial cells. Biol Pharm Bull 34: 324-329.
42. Park SH, Cheung LW, Wong AS, Leung PC, (2008) Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol 22: 2085-2098.